Key Points
Zoetis expects $1.61 EPS and $2.30B revenue on May 7, 2026.
Company beat EPS in three of last four quarters, signaling strong execution.
Watch companion animal growth, livestock demand, and margin stability.
Meyka AI B+ grade reflects solid fundamentals with balanced risk-reward.
Zoetis Inc. (ZTS) will report first-quarter 2026 earnings on May 7 after market close. The animal health leader faces analyst expectations of $1.61 earnings per share and $2.30 billion in revenue. This earnings preview matters because Zoetis has beaten EPS estimates in three of the last four quarters, signaling strong operational execution. The stock trades at $112.54 with a P/E ratio of 18.69, reflecting moderate valuation in the healthcare sector. Meyka AI rates ZTS with a grade of B+, indicating solid fundamentals and growth potential. Understanding what to watch helps investors prepare for potential market moves.
Earnings Estimates and Historical Performance
Analysts project Zoetis will deliver $1.61 EPS and $2.30 billion in revenue for Q1 2026. These estimates represent a critical test of the company’s earnings momentum heading into 2026.
Recent Quarter Results
Zoetis has demonstrated consistent earnings strength. In Q4 2025, the company reported $1.76 EPS, beating the $1.62 estimate by 8.6%. Revenue came in at $2.46 billion versus the $2.41 billion estimate. Q3 2025 showed similar resilience with $1.70 EPS against a $1.62 estimate. The February 2026 quarter delivered $1.48 EPS, slightly beating the $1.40 estimate. This three-quarter beat streak suggests management executes well on guidance.
Revenue Trend Analysis
Revenue estimates for Q1 2026 at $2.30 billion mark a slight decline from recent quarters. Q4 2025 revenue of $2.46 billion and Q3 2025 revenue of $2.40 billion both exceeded the current estimate. This sequential decline could reflect normal seasonal patterns in animal health or conservative analyst positioning. The company’s ability to maintain pricing power in companion animal products will be critical to watch.
What Investors Should Watch
Several key metrics will determine whether Zoetis meets or exceeds expectations on May 7. Investors should focus on segment performance, margin trends, and forward guidance.
Companion Animal Segment Growth
Companion animal products represent Zoetis’s fastest-growing segment. Watch for pricing momentum in dermatology and parasiticide products, which drive higher margins. The company’s recent acquisitions in this space should show meaningful contribution. Any slowdown in pet healthcare spending would be a red flag for the stock.
Livestock and Poultry Performance
Livestock segment results matter significantly given commodity price volatility. Feed costs and animal disease trends impact farmer spending on vaccines and antibiotics. Management commentary on international livestock demand, particularly in Europe and Asia, will guide full-year expectations. Strong livestock results would support the current earnings trajectory.
Operating Margin Expansion
Zoetis has shown improving operational efficiency. Operating margins of 38% demonstrate strong cost control. Watch for gross margin stability and SG&A expense management. Any margin compression would pressure EPS growth despite revenue strength. The company’s R&D spending at 7.4% of revenue supports future product launches.
Beat or Miss Prediction
Based on historical patterns, Zoetis appears positioned to beat Q1 2026 estimates. The company has exceeded EPS expectations in three of the last four quarters, establishing a credible beat track record.
EPS Beat Probability
The $1.61 EPS estimate appears achievable given recent performance. Q4 2025 beat by 8.6%, Q3 2025 beat by 4.9%, and February 2026 beat by 5.7%. This consistency suggests management has visibility into earnings drivers. A beat of 3-5% would place Q1 2026 EPS between $1.66 and $1.69, which aligns with the company’s historical execution pattern.
Revenue Considerations
Revenue estimates at $2.30 billion represent a more conservative positioning. Recent quarters have consistently exceeded revenue targets. If the company maintains pricing discipline and volume growth, a $2.32-2.35 billion result is plausible. Management’s ability to offset any volume softness with price increases will determine revenue performance.
Meyka AI Grade and Valuation Context
Meyka AI rates ZTS with a grade of B+, reflecting solid financial health and growth prospects. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests the stock offers balanced risk-reward at current levels.
Valuation Assessment
At 18.69 P/E, Zoetis trades near its historical average. The stock’s 52-week range of $111.27 to $172.23 shows significant volatility. Current price of $112.54 sits near the low end, suggesting potential upside if earnings meet expectations. The dividend yield of 1.83% provides income support. Strong ROE of 58% and ROA of 17% demonstrate efficient capital deployment.
Growth Metrics
Zoetis shows solid fundamentals with free cash flow yield of 4.8% and operating cash flow of $6.63 per share. The company’s debt-to-equity ratio of 2.85 reflects moderate leverage typical for healthcare. Five-year revenue growth per share of 52% and net income growth of 75% show strong historical expansion. These metrics support the B+ grade and suggest earnings growth should continue.
Final Thoughts
Zoetis enters Q1 2026 earnings with strong momentum and a credible beat track record. Analyst expectations of $1.61 EPS and $2.30 billion revenue appear achievable based on recent quarter performance. The company’s three-quarter EPS beat streak and consistent revenue outperformance suggest management execution remains solid. Watch companion animal segment growth, livestock demand trends, and margin stability for clues on full-year guidance. Meyka AI’s B+ grade reflects balanced fundamentals, though the stock’s 28.8% one-year decline suggests valuation has become attractive. Investors should focus on whether management raises 2026 guidance, which would validate the current earnings trajectory and potentially drive stock appreciation.
FAQs
What EPS and revenue does Zoetis need to beat estimates?
Analysts expect $1.61 EPS and $2.30B revenue. Based on recent beat patterns, Zoetis likely needs $1.66+ EPS and $2.32B+ revenue to exceed expectations. The company has beaten EPS in three of four recent quarters by 4-9%.
Has Zoetis beaten earnings estimates recently?
Yes. Zoetis beat EPS estimates in three of the last four quarters: Q4 2025 beat by 8.6%, Q3 2025 by 4.9%, and February 2026 by 5.7%. Only one quarter missed slightly. This track record suggests strong management execution.
What should investors watch during the earnings call?
Monitor companion animal segment growth, livestock demand trends, operating margin stability, and full-year 2026 guidance. Management commentary on pricing power, international markets, and acquisition integration will guide investor sentiment and stock direction.
What does Meyka AI’s B+ grade mean for ZTS?
The B+ grade reflects solid financial health, strong ROE of 58%, and balanced growth prospects. This grade factors in S&P 500 comparison, sector performance, and analyst consensus. It suggests neutral-to-buy positioning at current valuations.
Is Zoetis stock undervalued at $112.54?
At 18.69 P/E and near its 52-week low of $111.27, Zoetis appears reasonably valued. The stock’s 28.8% one-year decline suggests valuation has become attractive. Strong fundamentals and beat track record support potential upside if earnings meet expectations.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)